Trametinib Decreased Intracerebral Hemorrhages and Endothelial-to-Mesenchymal Transition in KRAS <sup>G12V</sup> -Induced Brain Arteriovenous Malformations in Mice
Our data demonstrate that trametinib improves bAVM pathology by reducing hemorrhagic risk and normalizing endothelial-to-mesenchymal transition. These findings suggest that trametinib is a promising agent to treat patients with bAVM.
Authors
- Eun Su Park (ORCID: https://orcid.org/0000-0002-4213-6681)
- Jaroslaw Aronowski (ORCID: https://orcid.org/0000-0002-9256-7973)
- Jakob Körbelin (ORCID: https://orcid.org/0000-0002-5435-7182)
- B. Freeman (ORCID: https://orcid.org/0000-0003-4295-0197)
- Jung-Eun Park (ORCID: https://orcid.org/0009-0004-9216-3719)
- Peng Roc Chen (ORCID: https://orcid.org/0000-0001-8438-132X)
- Samantha M. Wilfur
- Eunhee Kim (ORCID: https://orcid.org/0000-0002-7755-7291)
- Ohnmar Myint (ORCID: https://orcid.org/0000-0001-9004-4282)
- H. J. Park (ORCID: https://orcid.org/0000-0002-5326-9711)
- Shuning Huang
- Jin Young Jeong (ORCID: https://orcid.org/0009-0006-5163-0004)
Institutions
- Universität Hamburg (DE)
- Pt. Jawahar Lal Nehru Memorial Medical College (IN)
- Society of Interventional Radiology (US)
- University Medical Center Hamburg-Eppendorf (DE)
- Brown Foundation (US)
- Institute of Neuroimmunology of the Slovak Academy of Sciences (SK)
- The University of Texas Health Science Center (US)
Publication Details
- Journal
- Stroke
- Published
- 2025-12-18
- DOI
- https://doi.org/10.1161/strokeaha.125.052418
- Primary Topic
- Vascular Malformations Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00